Drug profile · INN
osimertinib mesylate
TAGRISSO
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
osimertinib mesylate (TAGRISSO) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN osimertinib mesylate
Brand TAGRISSO
Route ORAL
Formulation TABLET
Frequently asked questions
What is osimertinib mesylate?
osimertinib mesylate (TAGRISSO) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for osimertinib mesylate?
TAGRISSO is a marketed brand name for osimertinib mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of osimertinib mesylate?
osimertinib mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.